Modulating gut miocrobiota: A new strategy in the treatment of gout
10.12092/j.issn.1009-2501.2022.11.014
- Author:
Yu CHEN
1
;
Bing GU
1
;
Huanan LI
2
Author Information
1. College of Life Sciences, Jiangxi Science & Technology Normal University
2. Department of Traumatic Orthopedics, the Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine
- Publication Type:Journal Article
- Keywords:
gout;
gut miocrobiota;
inflammation response;
uric acid metabolism
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2022;27(11):1307-1314
- CountryChina
- Language:Chinese
-
Abstract:
Gout is a persistent increase in blood uric acid caused by purine and uric acid metabolism disorders, resulting in monosodium urate crystal deposition induced by recurrent inflammatory diseases, mainly manifested as elevated uric acid and inflammatory attacks. Studies have shown that gout and changes in the gut miocrobiota are mutually causal, and the gut miocrobiota can not only affect purine and uric acid metabolism but also regulate inflammatory response. Therefore, regulating the gut miocrobiota is expected to become a new strategy for the treatment of gout. This article starts from the regulation of purine and uric acid metabolism and inflammatory response by gut miocrobiota, so as to clarify the specific application of gut miocrobiota regulation as a new strategy for gout treatment.
